Meeting
2020 ASCO Virtual Scientific Program
Efficacy and safety of nivolumab for malignant mesothelioma in the real world.
Authors
Koji Mikami
Division of Respiratory Medicine, Department of Internal Medicine Department of Thoracic Oncology Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
Koji Mikami , Takashi Yokoi , Ryo Takahashi , Eisuke Shibata , Maiko Niki , Yasuhiro Nakajima , Yoshiki Negi , Hirotoshi Ishigaki , Akio Tada , Tomoki Higashiyama , Takao Kamei , Toshiyuki Minami , Kozo Kuribayashi , Takashi Kijima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9052)
DOI
10.1200/JCO.2020.38.15_suppl.9052
Abstract #
9052
Poster Bd #
245
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).
First Author: Roland Lang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.
First Author: Keitaro Shimozaki
Poster
2023 ASCO Breakthrough
Efficacy and safety of pembrolizumab in advanced neuroendocrine tumors (NETs): A meta-analysis of clinical trials.
First Author: Akshit Chitkara
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf